Atrion (NASDAQ:ATRI) Sees Large Volume Increase

Shares of Atrion Co. (NASDAQ:ATRI) saw unusually-high trading volume on Tuesday . Approximately 11,008 shares traded hands during trading, a decline of 36% from the previous session’s volume of 17,223 shares.The stock last traded at $413.00 and had previously closed at $399.83.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Atrion from a “hold” rating to a “sell” rating in a report on Monday.

Atrion Price Performance

The company’s fifty day simple moving average is $402.59 and its two-hundred day simple moving average is $364.60. The stock has a market cap of $746.57 million, a price-to-earnings ratio of 38.46 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last released its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The firm had revenue of $43.58 million for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were issued a $2.20 dividend. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.07%. Atrion’s dividend payout ratio is currently 79.78%.

Institutional Trading of Atrion

Several institutional investors and hedge funds have recently made changes to their positions in the company. Penn Mutual Asset Management LLC bought a new position in Atrion during the fourth quarter valued at about $1,949,000. Citizens Financial Group Inc. RI bought a new position in Atrion during the fourth quarter valued at about $1,114,000. Boston Trust Walden Corp grew its position in Atrion by 4.8% during the fourth quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock valued at $13,292,000 after buying an additional 1,609 shares during the period. Exchange Traded Concepts LLC bought a new position in Atrion during the third quarter valued at about $333,000. Finally, Jump Financial LLC bought a new position in Atrion during the fourth quarter valued at about $234,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.